Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:117-24.
doi: 10.4137/CMO.S6248. Epub 2012 Feb 20.

Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer

Michel Velez  1 , Belisario A Arango, Cesar A Perez, Edgardo S Santos
Affiliations

Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer

Michel Velez et al. Clin Med Insights Oncol. 2012.

Abstract

Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and women worldwide with projected 221,130 new cases and 156,940 deaths in the United States in 2011.1 Non-small cell lung cancer (NSCLC) represents more than 85% of the cases with most patients having either locally advanced or metastatic disease at the time of initial diagnosis, and approximately 60%-70% of them have an adenocarcinoma histologic subtype. In the last three years, we have seen several advances in the management of NSCLC, with several factors playing an important role in the treatment decision making process. Maintenance therapy has been added to the algorithm of NSCLC management and Pemetrexed has been studied as single agent or in combination in this setting with recent studies showing safety and improved progression free survival (PFS) and/or overall survival (OS), still the disease for the most part has a dismal outcome. More research work needs to be done to identify which patients truly benefit from these approaches, and to whom we should offer maintenance or switch maintenance vs. close observation.

Keywords: Pemetrexed; lung cancer; maintenance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pemetrexed mechanism of action.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.
    1. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV Non-Small Cell Lung Cancer. J Clin Oncol. 2002:1335–43. - PubMed
    1. Barata FJ, Parente B, Teixeira E, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs. 6 cycles of carboplatin and gemcitabine: P2–235. J Thorac Oncol. 2007;2(Suppl 4):S666.
    1. Park JO, Kim S-W, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007:5233–9. - PubMed
    1. Soon Y, Stockler MR, Boyer M, Askie L. Duration of chemotherapy for advanced non-small-cell lung cancer: An updated systematic review and meta-analysis. J Clin Oncol. 2008;26(15S):8013. - PubMed

LinkOut - more resources